Esaote S.p.A. turns 40 and is confirmed as a leading player in the world market for diagnostic imaging
PR95408
Esaote S.p.A. turns 40 and is confirmed as a leading player in the world market for diagnostic imaging with ultrasound systems, magnetic resonance imaging and information technology for healthcare
GENOA, Italy, Apr. 12, 2022 /PRNewswire=KYODO JBN --
Esaote S.p.A., a leading biomedical company in the diagnostic imaging sector -
in the fields of ultrasound, magnetic resonance and Information Technology for
health - celebrates forty years of activity.
Born from scratch in 1982, the Italian company - with headquarters in Genoa and
present today in 100 countries around the world - has immediately carved out a
primary role in the global market, focusing on innovation, research and
technology. The ultrasound system used by NASA in the early nineties for the
cardiovascular examinations of astronauts flying on the Shuttle was from
Esaote. The first MRI system dedicated to the limbs was developed by Esaote as
well as the fusion imaging technology.
"Imaging the Future, Everyday. Forty years of innovation for health since 1982"
is the event held at the Carlo Felice Theater in Genoa, with guests from all
over the world to kick off a Celebration Week.
"We are very proud to celebrate forty years in business and to be able to share
this milestone with our founders, with those who have worked with us all these
years and with the young colleagues who are our future. This event," declared
Franco Fontana, CEO of the Esaote Group, "comes to the end of a period of great
complexity, both for our market and for the whole world, during which Esaote
has never stopped investing and innovating, trying to pursue its objectives of
growth and research of new products. Efforts that allowed us to close a 2021
financial year in an extremely positive way, with consolidated revenues up to
231.3 million Euros (+ 5% compared to 2020) and order collection up by 18%
compared to the previous year.
"The draft financial statements, which have already been approved by the Board
of Directors, will be presented to the Shareholders' Meeting at the end of the
month: the positive and strong net result compared to the previous year
testifies the great progress of the Group also on international markets, which
constitute the 70% of total revenues. A balance that rewards the high
technological level of the company which, in the course of 2021, presented
significant innovations on the market and particularly appreciated by our
customers, with the launch of two new latest generation ultrasound systems and
the first open magnetic resonance total-body made by Esaote."
The Group employs over 1,250 employees, 20% of whom are engaged in Research and
Development, a sector in which the company invests about 11% of its revenues.
Over the past year, the company's workforce has grown by 8% worldwide. Over 100
new hires to implement the renewal of the generational and professional mix,
with growth especially in the R&D, Sales and Marketing sectors.
Photo - https://mma.prnewswire.com/media/1793999/Esaote.jpg
Logo - https://mma.prnewswire.com/media/1793998/Esaote_Logo.jpg
Source: Esaote
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。